Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label Clinical Study on the Efficacy and Safety of U01 (ssCART-19) in the Treatment of Relapsed or Refractory B-Cell Lymphoma

NCT06987916 is registered in ClinicalTrials.gov with Shanghai Tongji Hospital, Tongji University School of Medicine as lead sponsor.

NCT NCT06987916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06987916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label Clinical Study on the Efficacy and Safety of U01 (ssCART-19) in the Treatment of Relapsed or Refractory B-Cell Lymphoma
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 22, 2025
Completion date
April 22, 2030
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma